Corvigno, Sara
Badal, Sunil
Spradlin, Meredith L.
Keating, Michael
Pereira, Igor
Stur, Elaine
Bayraktar, Emine
Foster, Katherine I. http://orcid.org/0000-0001-7714-246X
Bateman, Nicholas W. http://orcid.org/0000-0002-4425-9511
Barakat, Waleed
Darcy, Kathleen M. http://orcid.org/0000-0003-2888-2968
Conrads, Thomas P. http://orcid.org/0000-0003-4742-3281
Maxwell, G. Larry
Lorenzi, Philip L. http://orcid.org/0000-0003-0385-7774
Lutgendorf, Susan K.
Wen, Yunfei
Zhao, Li
Thaker, Premal H.
Goodheart, Michael J.
Liu, Jinsong
Fleming, Nicole
Lee, Sanghoon
Eberlin, Livia S.
Sood, Anil K. http://orcid.org/0000-0003-4242-1762
Article History
Received: 18 October 2022
Accepted: 26 September 2023
First Online: 3 November 2023
Competing interests
: N.F. declares that she is a consultant for GSK and Immunogen. L.S.E. declares that she receives funding from Thermo Fisher, Merck & Co, Waters corporation, and Eli Lilly and has stocks in MS Pen Technologies. A.K.S. declares that he is a shareholder of BioPath, and is a consultant for Merck, AstraZeneca, Onxeo, ImmunoGen, Ivlon, GSK, and Kiyatec. The remaining authors declare no competing financial or non-financial interests.